The second anti–PD-1 Ab, nivolumab, was developed by Bristol Myers Squibb and approved by the FDA in 2014 to treat advanced melanoma, squamous cell lung cancer, renal cell carcinoma (RCC), and Hodgkin lymphoma (Sanaei et al., 2021). Here, PDCD1 is linked to renal cell carcinoma.